115 related articles for article (PubMed ID: 17927978)
1. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression.
Yang S; Park K; Turkson J; Arteaga CL
Exp Cell Res; 2008 Jan; 314(2):413-9. PubMed ID: 17927978
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Kim Y; Apetri M; Luo B; Settleman JE; Anderson KS
Mol Cancer Res; 2015 Apr; 13(4):765-74. PubMed ID: 25573954
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling.
Samarakoon R; Higgins SP; Higgins CE; Higgins PJ
J Mol Cell Cardiol; 2008 Mar; 44(3):527-38. PubMed ID: 18255094
[TBL] [Abstract][Full Text] [Related]
4. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
5. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
Mueller KL; Hunter LA; Ethier SP; Boerner JL
Cancer Res; 2008 May; 68(9):3314-22. PubMed ID: 18451158
[TBL] [Abstract][Full Text] [Related]
6. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z; Jiang S; Du R; Petri ET; El-Telbany A; Chan PS; Kijima T; Dietrich S; Matsui K; Kobayashi M; Sasada S; Okamoto N; Suzuki H; Kawahara K; Iwasaki T; Nakagawa K; Kawase I; Christensen JG; Hirashima T; Halmos B; Salgia R; Boggon TJ; Kern JA; Ma PC
Oncogene; 2009 Jan; 28(4):518-33. PubMed ID: 19015641
[TBL] [Abstract][Full Text] [Related]
9. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
Fu YN; Yeh CL; Cheng HH; Yang CH; Tsai SF; Huang SF; Chen YR
Oncogene; 2008 Feb; 27(7):957-65. PubMed ID: 17653080
[TBL] [Abstract][Full Text] [Related]
10. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
[TBL] [Abstract][Full Text] [Related]
11. An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells.
Nakamura N; Chin H; Miyasaka N; Miura O
J Biol Chem; 1996 Aug; 271(32):19483-8. PubMed ID: 8702638
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
[TBL] [Abstract][Full Text] [Related]
13. The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants.
Chung BM; Dimri M; George M; Reddi AL; Chen G; Band V; Band H
Oncogene; 2009 Apr; 28(16):1821-32. PubMed ID: 19305428
[TBL] [Abstract][Full Text] [Related]
14. The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Kancha RK; Peschel C; Duyster J
J Thorac Oncol; 2011 Feb; 6(2):387-92. PubMed ID: 21252719
[TBL] [Abstract][Full Text] [Related]
15. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
16. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Zou B; Lee VHF; Yan H
BMC Bioinformatics; 2018 Mar; 19(1):88. PubMed ID: 29514601
[TBL] [Abstract][Full Text] [Related]
17. Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
Okutani Y; Kitanaka A; Tanaka T; Kamano H; Ohnishi H; Kubota Y; Ishida T; Takahara J
Oncogene; 2001 Oct; 20(45):6643-50. PubMed ID: 11641791
[TBL] [Abstract][Full Text] [Related]
18. LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers.
Chen C; Liu WR; Zhang B; Zhang LM; Li CG; Liu C; Zhang H; Huo YS; Ma YC; Tian PF; Qi Q; Li JJ; Tang Z; Zhang ZF; Giaccone G; Yue DS; Wang CL
Cancer Lett; 2020 Aug; 486():58-70. PubMed ID: 32439420
[TBL] [Abstract][Full Text] [Related]
19. c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.
Marcotte R; Zhou L; Kim H; Roskelly CD; Muller WJ
Mol Cell Biol; 2009 Nov; 29(21):5858-71. PubMed ID: 19704002
[TBL] [Abstract][Full Text] [Related]
20. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival.
Lypova N; Telang S; Chesney J; Imbert-Fernandez Y
J Biol Chem; 2019 Jul; 294(27):10530-10543. PubMed ID: 31126985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
